Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results
Provided By GlobeNewswire
Last update: May 2, 2025
On track for six major study readouts across four programs over the next 12 months
Ready to initiate pivotal studies in two developmental and epileptic encephalopathy (DEE) programs in mid-year 2025: EMERALD for broad DEEs with relutrigine and EMBRAVE3 for SCN2A GoF with elsunersen
Read more at globenewswire.com
